← Back to Clinical Trials
Recruiting NCT07678034

NCT07678034 Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Shoulder Prosthesis System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07678034
Status Recruiting
Phase
Sponsor TIPMED Medical Device Manufacturing Ltd. Co.
Condition Glenohumeral Osteoarthritis
Study Type OBSERVATIONAL
Enrollment 54 participants
Start Date 2025-06-16
Primary Completion 2030-03-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Tipmed™ Reverse Shoulder Prosthesis SystemTipmed™ Shoulder Prosthesis System (Hemiarthroplasty Configuration)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 54 participants in total. It began in 2025-06-16 with a primary completion date of 2030-03-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is designed as a prospective, multicenter, observational post-market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the Tipmed™ Shoulder Prosthesis System at 12 months postoperatively. The study population includes adult patients who undergo reverse shoulder arthroplasty (RSA) or shoulder hemiarthroplasty (HA) using the Tipmed™ implant systems due to various clinical indications such as osteoarthritis, rotator cuff arthropathy, or proximal humerus fractures. The main objective is to gather real-world clinical evidence on the 12-month post-operative safety profile, potential complications, and functional outcomes of the device during routine clinical practice.

Eligibility Criteria

Inclusion Criteria: * Individuals aged 18 years and older, * Male or female participants, * Participants who have undergone Reverse Shoulder Arthroplasty or Shoulder Hemiarthroplasty for any valid indication, * Participants in whose surgical procedure the Tipmed™ Shoulder Prosthesis System product configurations were utilized. * Participants who are not legally restricted (e.g., military personnel, convicts, or individuals under legal guardianship). * Participants who have voluntarily signed the written Informed Consent Form (ICF). Exclusion Criteria: * Concurrent participation in any other interventional clinical trial.

Contact & Investigator

Central Contact

Yasemin Önel, Sponsor Rep

✉ yaseminonel@tipmed.com

📞 +90 232 479 33 22

Principal Investigator

Özgün Karakuş, Assoc. Prof.

STUDY DIRECTOR

Republic of Turkey Ministry of Health Balıkesir Provincial Health Directorate, Atatürk City Hospital

Frequently Asked Questions

Who can join the NCT07678034 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Glenohumeral Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07678034 currently recruiting?

Yes, NCT07678034 is actively recruiting participants. Contact the research team at yaseminonel@tipmed.com for enrollment information.

Where is the NCT07678034 trial being conducted?

This trial is being conducted at Balıkesir, Turkey (Türkiye), Istanbul, Turkey (Türkiye), Izmir, Turkey (Türkiye), Izmir, Turkey (Türkiye).

Who is sponsoring the NCT07678034 clinical trial?

NCT07678034 is sponsored by TIPMED Medical Device Manufacturing Ltd. Co.. The principal investigator is Özgün Karakuş, Assoc. Prof. at Republic of Turkey Ministry of Health Balıkesir Provincial Health Directorate, Atatürk City Hospital. The trial plans to enroll 54 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology